[Antons KA, Williams CD, Baker SK, Phillips PS. (2006). Clinical perspectives of statin-induced rhabdomyolysis. Am J Med119(5): 400–409.]Search in Google Scholar
[Buse J. (2003). Statin Treatment in Diabetes Mellitus. Clin Diabetes21: 168–72.]Search in Google Scholar
[Cadila Healthcare Ltd. (2012). Salts of Rosuvastatin. International patent application WO 2012/073256 A1. 2012.06.07.]Search in Google Scholar
[Famularo G, Miele L, Minisola G, Grieco A. (2007). Liver toxicity of rosuvastatin therapy. World J Gastroenterol13(8): 1286–1288.]Search in Google Scholar
[Guidance for Industry; Bioanalytical Method Validation, May 2001. U.S. Food and Drug Administration. Available from: https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf [Access 13 November 2017]]Search in Google Scholar
[Leiter LA, Rosenson RS, Stein E, Reckless JPD, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F. (2007). Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis194(2): e154–e164.]Search in Google Scholar
[Macdonald JS, Halleck MM. (2004). The Toxicology of HMG–CoA Reductase Inhibitors: Prediction of Human Risk. Toxicol Pathol32(S2): 26–41.]Search in Google Scholar
[Marrer E, Dieterle F. (2010). Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol243: 167–179.]Search in Google Scholar
[Olsson AG, McTaggart F, Raza A. (2002). Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev20(4): 303–328.]Search in Google Scholar
[Pasternak RC, Smith SC, Bairey-Merz, CN, Grundy SM, Cleeman JI, Lenfant C. (2002). ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke33: 2337–2341.]Search in Google Scholar
[Pharmacology review(s) of rosuvastatin calcium. U.S. Food and Drug Administration.available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor.cfm [Accesses 21 June 2017].]Search in Google Scholar
